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New Guidance on Managing Inpatient Hyperglycaemia during the COVID-19 Pandemic 
Rayman G, Lumb A, Kennon B, Cottrell C, Nagi D, Page E, Voigt D, Courtney H, Atkins H, Platts J, Higgins K, 
Dhatariya K, Patel M, Narendran P, Kar P, Newland-Jones P, Stewart R, Burr O, Thomas S. 
The COVID-19 pandemic has had a dramatic impact on the provision of acute inpatient care with 
specialists from all disciplines having to manage patients outside of their usual speciality areas. In many 
UK hospitals diabetes consultants and diabetes inpatient specialist nurses have been redeployed to the 
wards to care for COVID-19 positive or suspected cases.  Consequently, clinicians relatively unfamiliar with 
managing hyperglycaemia have been required to do so as the usual input from diabetes specialist teams 
has not been possible in many areas. 
The National Diabetes Inpatient COVID-19 Response Group was formed to provide guidance to those 
involved in the care of inpatients with diabetes during this crisis. We have published in a previous issue of 
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this journal guidance on care at the ‘front door’ aimed at emergency departments and admitting teams1. 
We now present guidance on the management of inpatient hyperglycaemia (Figure 1). We recognise that 
most hospitals will already have established local guidance in place. The current guidance is intended to 
help supplement and update existing guidance with a particular reference to supporting those less 
experienced in insulin use. In this respect, it is tailored to manage hyperglycaemia but as much as possible 
reducing the risk of overcorrection resulting in hypoglycaemia. It thus sets more liberal glycaemic targets 
than have been suggested in previous UK guidelines2. The COVID specific diabetes algorithms aim to 
achieve a ‘lower’ target of 6.0 mmol/L (higher than the previous of 4.0mmol/L) yet to keep blood glucose 
levels less than 10.0 mmol/L with up to 12.0 mmol/L being acceptable. 
Uniquely, it provides 3 different correction regimes for rapid acting analogue insulin based on the 
information available to the clinician. Firstly, if the person with diabetes knows their own ‘correction 
dose’ this should be used (e.g. for people with type 1 diabetes who are DAFNE trained, 1 unit reduces the 
blood glucose by 3.0 mmol/L). Secondly, if the total daily dose is known the correction is based on 
intervals of less than 50 units/day, 50-100 units/day and over 100 units/day. Finally, where none of the 
previous are known, the correction is based on weight with intervals of less than 50 kg, 50-100 kg and > 
100 kg (for insulin naïve people or those newly presenting).
The guidance recommends commencement of a basal insulin if hyperglycaemia persists after several 
correction doses of rapid acting insulin within a 24 hr period. The algorithm recommends a starting dose 
related to the person’s weight and specific issues such as age, fragility and renal function. There are then 
dosing regimens related to the particular basal insulin available in individual hospitals. There is also a dose 
adjustment regimen for the basal regimen based on the blood glucose levels immediately prior to the 
timing of the basal insulin. 
Finally, the guidance recognises that the insulin dose may need adjustment, particularly the basal insulin 
dose when there is a change in insulin sensitivity such as can occur with improving infection, reduction in 
corticosteroid treatment and in those recovering from COVID-19 related insulin resistance. 
Although, this guidance has been introduced for use during the present pandemic it is possible that this 
more judicious glucose target that has been previously advocated by some3 and the early intervention 
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NATIONAL INPATIENT DIABETES COVID-19 RESPONSE GROUP*
Use when:
 o Glucose above 12 mmol/l and a correction dose is appropriate for the individual patient
 o DKA/HHS not present
Can be used in place of variable rate intravenous insulin when infusion pumps not available
  DO NOT use for people with COVID-19 causing severe insulin resistance in the ICU. Contact your local diabetes 
team for advice in this circumstance.
  After 9pm consider risk of hypoglycaemia overnight when thinking about the use of a corrective dose
COncise adVice on Inpatient 
Diabetes (COVID:Diabetes): 
GUIDANCE FOR MANAGING 
INPATIENT HYPERGLYCAEMIA
IF GLUCOSE > 12 MMOL/L AND NO INSULIN ADMINISTERED IN 
PREVIOUS 4 HRS CONSIDER A CORRECTIVE DOSE OF RAPID-ACTING 
ANALOGUE INSULIN (NOVORAPID®/HUMALOG®/APIDRA®)
 › Re-check glucose after 4 hours OR before next meal - further action may be required
 › Target glucose 6-10 mmol/l – aiming for higher end of range (up to  
12 mmol/l acceptable)
 › Dose decided using one of the following 3 factors and the table below. Factors 
are listed in order of importance:
1. If person uses pre-existing correction ratio (CR) (e.g. 1 unit insulin lowers 
glucose by 3 mmol/l) this should be used 
2. If person using insulin but doesn’t have correction ratio, use their usual 
total daily insulin dose (TDD)
3. If person not previously using insulin, or dose is unknown, use their weight
 › If the person has rapid-acting insulin with each meal the corrective dose can 
be added to their mealtime dose if appropriate.
GLUCOSE
(MMOL/L)
CR* = 1UNIT   
4 MMOL/L OR
TDD** LESS THAN 
50 UNITS OR
WEIGHT LESS  
THAN 50KG
CR* = 1UNIT   
3 MMOL/L OR




CR* = 1UNIT   
2 MMOL/L OR
TDD** OVER 100 
UNITS OR
WEIGHT OVER  
100 KG
12.0-14.9 1 1 2
15.0-16.9 2 2 3
17.0-18.9 2 3 4
19.0-20.9 3 3 5
21.0-22.9 3 4 6
23.0-24.9 4 5 7
25.0-27.0 4 5 8
Over 27 5 6 9
*CR = Correction ratio, **TDD = total daily insulin dose
  It is recommended that glucose is checked at least 4 times per day in 
people treated with insulin
LONG-ACTING INSULIN  
(LEVEMIR®/ ABASAGLAR®/LANTUS®/SEMGLEE®/ HUMULIN I®/
INSULATARD®/INSUMAN BASAL®)
 › Already using long-acting insulin: Continue and titrate dose (see tables below)
 › NOT already using long-acting insulin: If 2 or more glucose readings in 24 
hrs are > 12 mmol/l (eg, 2 or more corrective doses in previous 24 hrs)
 » ADD long-acting insulin - total dose 0.25 units/kg/day (eg, 0.25 x 80kg = 20 
units OD OR 10 units BD depending on the choice of basal insulin - see below). 
 » NOTE if:
 - Older (>70 yrs) or frail 
 - Serum creatinine >175 umol/l
Use a reduced long-acting insulin dose of 0.15 units/kg (eg 0.15 x 80kg = 
12 units OD OR 6 units BD)
Recommended options (all acceptable – refer to local protocols):
Levemir®
Insulin detemir  
100 units/ml (U100)
 › Two equal doses of 0.125 units/kg, 12 hrs apart 
 › Not available in vials so insulin pen needles 
must be available to use with a pen device*
 › Can adjust either dose
Abasaglar®/Lantus® 
/Semglee®
Insulin glargine  
100 units/ml (U100)
 › Single dose of 0.25 units/kg/24 hrs (minimises 
patient contact) or
 › Split above into 2 equal doses, 12 hrs apart
 › Abasaglar®/Semglee® not available in vials so 
insulin pen needles must be available to use 
with an insulin pen device** 
Humulin I®/Insulatard® 
/Insuman Basal®
Isophane insulin  
100 units/ml (U100) 
 › Two equal doses of 0.125 units/kg/10-14 hrs apart
 › Particularly suited to steroid treatment – dose 
given as 3 total long-acting insulin dose am :3 
total long-acting insulin dose pm
* Only speciic insulin syringes/needles should be used to administer insulin  
 from vials 















DOSE ADJUSTMENT FOR LONG-ACTING INSULIN
Doses can be titrated daily, although longer-acting insulins may take 48-72 hours to reach steady state. Dose adjustments will afect blood glucose throughout the day.
ONCE daily long-acting insulin TWICE daily long-acting insulin
GLUCOSE LEVEL JUST 
BEFORE INSULIN DOSE
GLUCOSE LEVEL JUST BEFORE MORNING  
INSULIN DOSE
JUST BEFORE EVENING  
INSULIN DOSE
<4mmol/L Reduce insulin by 20% <4mmol/L Reduce evening insulin  by 20% Reduce morning insulin by 20%
4.1-6mmol/L Reduce insulin by 10% 4.1-6mmol/L Reduce evening insulin by 10% Reduce morning insulin by 10%
6.1-12mmol/L No change 6.1-12mmol/L No change No change
12.1-18mmol/L Increase insulin by 10% 12.1-18mmol/L Increase evening insulin 10% Increase morning insulin by 10%
>18mmol/L Increase insulin by 20% >18mmol/L Increase evening insulin by 20% Increase morning insulin by 20%
Dose reduction should also be considered in the following circumstances:
 › Improving infection (as measured by falling CRP)
 › Enteral feed reducing or stopping
 › Corticosteroid treatment reducing or stopping
 › End of life care
  In people recovering from COVID-19-related insulin resistance, doses may need to be reduced RAPIDLY to avoid hypoglycaemia.
As noted above, severe insulin resistance has been noted in some people with COVID-19 in the ICU. In this circumstance, suggested alternative treatment 
strategies include four times daily doses of Levemir ® or twice daily doses of Lantus ®. 
Contact your local diabetes team for advice.
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